首页> 外文期刊>Drug Design, Development and Therapy >A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients
【24h】

A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients

机译:口服控释吗啡和羟考酮与丁丙诺啡和芬太尼透皮制剂治疗癌症严重疼痛的比较

获取原文
           

摘要

Aim of the study: To compare analgesia and adverse effects during oral morphine and oxycodone and transdermal fentanyl and buprenorphine administration in cancer patients with pain. Patients and methods: Cancer patients treated at home and in outpatient clinics with severe pain (numerical rating scale score 6–10) fail to respond to non-opioids and/or weak opioids. All patients were randomized to either morphine, oxycodone, fentanyl or buprenorphine and divided into subgroups with predominant neuropathic and nociceptive pain component. Doses of opioids were titrated to satisfactory analgesia and acceptable adverse effects intensity. Patients were assessed at baseline and followed for 28 days. In all patient groups, immediate-release oral morphine was the rescue analgesic and lactulose 10 mL twice daily was the prophylaxis of constipation; no antiemetics were used as prophylaxis. Results: A total of 62 patients participated and 53 patients completed the study. Good analgesia was obtained for all 4 opioids, for both nociceptive and neuropathic pain. The use of co-analgesics was greater in patients with neuropathic pain. Morphine treatment was associated with less negative impact of pain on ability to walk, work and activity (trend) according to Brief Pain Inventory-Short Form scores and less consumption of rescue morphine. The most common adverse effects included nausea and drowsiness, which increased at the beginning of the treatment and gradually decreased over the days to come. Appetite, well-being, anxiety, depression, and fatigue improved. There was no constipation (the Bowel Function Index scores were within normal range) during the treatment with all opioids. No changes were seen for constipation, vomiting and dyspnea. Conclusion: All opioids were effective and well-tolerated. Morphine was the most effective in the improvement in some of the Brief Pain Inventory-Short Form items regarding negative impact of pain on patients’ daily activities. Prophylaxis of constipation was effective; antiemetics may be considered for nausea prevention.
机译:研究的目的:比较疼痛的癌症患者口服吗啡和羟考酮以及经皮芬太尼和丁丙诺啡的镇痛作用和不良反应。患者和方法:在家中和门诊就诊且患有严重疼痛(数字评分量表评分为6-10)的癌症患者对非阿片类药物和/或弱阿片类药物无反应。所有患者均随机分为吗啡,羟考酮,芬太尼或丁丙诺啡,并分为具有主要神经性和伤害性疼痛成分的亚组。将阿片类药物的剂量滴定至令人满意的镇痛作用和可接受的不良反应强度。在基线时评估患者并随访28天。在所有患者组中,速释口服吗啡是急救止痛药,乳果糖10 mL每天两次预防便秘。没有使用止吐药来预防。结果:总共62例患者参加,53例患者完成了研究。对于所有4种阿片类药物,无论是伤害性疼痛还是神经性疼痛,均具有良好的镇痛效果。在神经性疼痛患者中,联合镇痛药的使用更多。根据简短疼痛量表-简短表格评分,吗啡治疗与疼痛对行走,工作和活动(趋势)的负面影响较小,而救援吗啡的消耗较少。最常见的不良反应包括恶心和嗜睡,它们在治疗开始时有所增加,并在以后的几天中逐渐减轻。食欲,健康,焦虑,抑郁和疲劳得到改善。所有阿片类药物治疗期间均无便秘(肠功能指数评分在正常范围内)。便秘,呕吐和呼吸困难未见变化。结论:所有阿片类药物均有效且耐受性良好。吗啡是改善疼痛简短表中某些最有效的方法,该方法涉及疼痛对患者日常活动的负面影响。预防便秘是有效的;可以考虑使用止吐药来预防恶心。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号